<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03479762</url>
  </required_header>
  <id_info>
    <org_study_id>NN8022-4246</org_study_id>
    <secondary_id>U1111-1185-3276</secondary_id>
    <secondary_id>EUPAS23369</secondary_id>
    <nct_id>NCT03479762</nct_id>
  </id_info>
  <brief_title>In Market Utilisation of Liraglutide Used for Weight Management in the UK: a Study in the CPRD Primary Care Database</brief_title>
  <official_title>In Market Utilisation of Liraglutide Used for Weight Management in the UK: a Study in the CPRD Primary Care Database</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is conducted in Europe. The aim of this study is to investigate the usage of
      liraglutide for weight management in clinical practice using the CPRD (Clinical Practice
      Research Datalink) primary care database.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">April 13, 2018</start_date>
  <completion_date type="Anticipated">July 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 15, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with a BMI above or equal to 30 kg/m^2 (Saxenda® only)</measure>
    <time_frame>Less than 6 months before the date of the first prescription</time_frame>
    <description>Number</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with a BMI above or equal to 27 kg/m^2 and below 30 kg/m^2 and 1 or more comorbidities (Saxenda® only)</measure>
    <time_frame>Less than 6 months before the date of the first prescription</time_frame>
    <description>With at least 1 relevant comorbidity: (Dysglycaemia, hypertension, dyslipidaemia, obstructive sleep apnoea and/or other weight related comorbidities)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with a BMI above or equal to 27 kg/m^2 and less than 30 kg/m^2 and no comorbidities (Saxenda® only)</measure>
    <time_frame>Less than 6 months before the first prescription</time_frame>
    <description>None of the relevant comorbidities: (Dysglycaemia, hypertension, dyslipidaemia, obstructive sleep apnoea and/or other weight related comorbidities)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with BMI below 27 kg/m^2 (Saxenda® only)</measure>
    <time_frame>Less than 6 months before the first prescription</time_frame>
    <description>Number</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with less than 5% weight loss and continuing treatment (Saxenda® only)</measure>
    <time_frame>Week 0 (first prescription) to week 16; week 24</time_frame>
    <description>Number</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean weight loss in patients not treated according to stopping rule (Saxenda® only)</measure>
    <time_frame>Week 0 (first prescription) to week 16; week 24</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with a BMI not measured (Saxenda® only)</measure>
    <time_frame>Less than 6 months before the first prescription</time_frame>
    <description>Number</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with at least 5% weight loss and continuing treatment (Saxenda® only)</measure>
    <time_frame>Week 16 - week 24</time_frame>
    <description>Number</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients fulfilling at least one of the following: 1) a prescription interval corresponding to a daily dose of 3.0 mg, 2) dose information of 3.0 mg per day, or 3) indication of weight management (Victoza® only)</measure>
    <time_frame>Within 4-12 weeks from the date of the first prescription</time_frame>
    <description>Number of patients with Victoza® prescriptions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of initiators with other GLP-1 receptor agonists prescribed during continued treatment with Saxenda® (Saxenda® only)</measure>
    <time_frame>From date of first prescription until 24 months</time_frame>
    <description>Continued treatment is defined as no gaps of more than 30 days between assumed prescription end and the subsequent prescription date</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of initiators with other products for weight management prescribed during continued treatment with Saxenda® (Saxenda® only)</measure>
    <time_frame>From date of first prescription until 24 months</time_frame>
    <description>Continued treatment is defined as no gaps of more than 30 days between assumed prescription end and the subsequent prescription date</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients who have reached 3.0 mg (Saxenda® only)</measure>
    <time_frame>12 weeks from time of first prescription</time_frame>
    <description>Number</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with a treatment duration of 0-6 months (Saxenda® only)</measure>
    <time_frame>Month 6</time_frame>
    <description>Number</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with a treatment duration of 7-12 months (Saxenda® only)</measure>
    <time_frame>Month 12</time_frame>
    <description>Number</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with a treatment duration of 13-18 months (Saxenda® only)</measure>
    <time_frame>Month 18</time_frame>
    <description>Number</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with a treatment duration of 19-24 months (Saxenda® only)</measure>
    <time_frame>Month 24</time_frame>
    <description>Number</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with a treatment duration of 25-36 months (Saxenda® only)</measure>
    <time_frame>Month 36</time_frame>
    <description>Number</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with a treatment duration of 37-48 months (Saxenda® only)</measure>
    <time_frame>Month 48</time_frame>
    <description>Number</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with a treatment duration of 49-60 months (Saxenda® only)</measure>
    <time_frame>Month 60</time_frame>
    <description>Number</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with ongoing treatment (current users) (Saxenda® only)</measure>
    <time_frame>Month 60</time_frame>
    <description>Number</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Obesity</condition>
  <condition>Overweight</condition>
  <arm_group>
    <arm_group_label>Liraglutide</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liraglutide</intervention_name>
    <description>No treatment given</description>
    <arm_group_label>Liraglutide</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients in the CPRD primary care database who have been prescribed liraglutide after the
        UK launch of Saxenda® (and have no liraglutide prescriptions in the previous 12 months)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        -New initiators of liraglutide (unbranded, or branded prescription, i.e. Saxenda® or
        Victoza®), who have no liraglutide prescriptions in the twelve months prior to index date
        (time of first prescription). Patients must be research standard (registered as
        &quot;acceptable&quot; in the database) with at least one year of up-to-standard registration prior
        to their index date

        Exclusion Criteria:

        -Not applicable
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Reporting Anchor and Disclosure (1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Soeborg</city>
        <zip>2860</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>March 21, 2018</study_first_submitted>
  <study_first_submitted_qc>March 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2018</study_first_posted>
  <last_update_submitted>April 20, 2020</last_update_submitted>
  <last_update_submitted_qc>April 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liraglutide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>According to the Novo Nordisk disclosure commitment on novonordisk-trials.com</ipd_description>
    <ipd_url>http://novonordisk-trials.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

